Skip to content

Treatment of Post-Traumatic Brain Injury (Post-TBI) Fatigue With Light Therapy

Treatment of Post-TBI Fatigue With Light Therapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01725750
Enrollment
88
Registered
2012-11-14
Start date
2012-11-30
Completion date
2017-06-30
Last updated
2019-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatigue, Traumatic Brain Injury

Keywords

Traumatic Brain Injury, TBI, Fatigue, Post-TBI Fatigue, PTBIF, Depressed Mood, Excessive Daytime Sleepiness, Circadian Rhythm, Anxiety, Cognitive Dysfunction, Intervention, Treatment

Brief summary

This study aims to evaluate the efficacy of 4 weeks of daily light exposure in reducing Post-Traumatic Brain Injury (TBI) Fatigue immediately post-treatment and at a one-month follow up. The investigators hypothesize that individuals receiving 4 weeks of bright white light treatment will report significant reductions in fatigue compared to individuals receiving dim red light treatment for the same duration of time, and that these treatment effects will be maintained one month after treatment completion.

Detailed description

To determine the efficacy of bright white light exposure compared to dim red light exposure in reducing post-TBI fatigue, an 8-week, randomized parallel-group clinical trial will be performed. Outcome assessment will be blinded. Participants will complete a baseline battery (T1) including 72 hours of actigraphy. Participants will then be randomized to either the Bright White Light (BWL) or the Dim Red Light (DRL) group. After 4 weeks of daily, 30-minute light treatments, the baseline battery will be re-administered (T2) along with 3 more days of Actigraphy. A follow-up assessment involving the same measures will be administered 1 month-post cessation of light therapy (T3). Participant treatment allocations will be masked for research team members conducting outcome measures. Secondary outcome measures will be administered to explore the effects of light therapy on mood, daytime sleepiness, sleep quality, circadian rhythms, anxiety, cognition and life satisfaction.

Interventions

Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box.

DEVICEDim Red Light (DRL)

A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box.

Sponsors

Icahn School of Medicine at Mount Sinai
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Documented TBI of any severity * At least 6 months post injury * Presence of clinically significant fatigue, operationalized as a score of 22 or more on the Multidimensional Assessment of Fatigue * Age 18 or older * English speaking

Exclusion criteria

* Neurological disease other than TBI * Pregnancy (because of pregnancy fatigue) * Medical illness causing fatigue, such as anemia, hypothyroidism, HIV, renal failure, cirrhosis or cancer treatment in the past year * Current major depressive episode or substance abuse * Diagnosed sleep disorder or high risk for sleep apnea * History of bipolar disorder or manic or hypomanic episodes * Current chronic, severe headaches * Sensitivity to bright light * History of retinal damage or disease

Design outcomes

Primary

MeasureTime frameDescription
Multidimensional Assessment of Fatigue (MAF)baseline, 4 weeks, 8 weeksMultidimensional Assessment of Fatigue (MAF) yields a Global Fatigue Index (GFI), assessing 5 dimensions of fatigue: distress, degree, severity, impact on ADLs and frequency of fatigue in the past week, and it yields a composite score. GFI full score from 0-50, with a higher score indicating more severe fatigue, fatigue distress, or impact on activities of daily living.

Secondary

MeasureTime frameDescription
Neuro-QOL Depression and Sleepbaseline, 4 weeks, 8 weeksThe Neuro-QOL Depression and Sleep measures the physical, mental, and social effects experienced by adults and children living with neurological conditions. Raw scores were converted to T-Scores; from 0-100, with a T = 50 indicating average function compared to the reference population and a standard deviation of 10, with a higher score indicating worse function.
Epworth Sleepiness Scale (ESS)baseline, 4 weeks, 8 weeksThe Epworth Sleepiness Scale (ESS) will also be used, to assess daytime sleepiness; it is an 8-item measure that asks about the probability of dozing or sleeping during typical daytime activities and has been widely used in TBI research. Scores correlate well with objective measures of speed of daytime sleep onset. The test is a list of eight situations in which the participate rates tendency to become sleepy on a scale of 0, no chance of dozing, to 3, high chance of dozing for each item. Total scale from 0 to 24, with higher score indicating severe excessive daytime sleepiness.
CNS Vital Signs TBI Rehab Toolboxbaseline, 4 weeks, 8 weeksThe Centre for Neuro Skills Vital Signs TBI Rehab Toolbox is a brief, 25-minute computerized cognition battery; it emphasizes those cognitive functions that are the most likely to respond to alerting effects of light (vigilance, attention, speed) and has multiple forms for serial assessment. The scores are reported as Standard Scores, with mean = 100 and standard deviation = 15. Higher scores are correlated with better outcomes.
Cognitive Failures Questionnairebaseline, 4 weeks, 8 weeksThe Cognitive Failures Questionnaire (CFQ)100 is a 25-item self-report inventory, with items measuring difficulties in several cognitive domains (e.g., memory, perception), each item scored from 0 (never) to 4 (very often), with total scale from 0 - 100, with higher score indicating worse outcome.
Neuro-QOL Anxietybaseline, 4 weeks, 8 weeksThe Neuro-QOL Anxiety measure. Raw scores were converted to T-Scores; from 0-100, with a T = 50 indicating average function compared to the reference population and a standard deviation of 10, with a higher score indicating worse anxiety.
TBI-QOL Fatiguebaseline, 4 weeks, 8 weeksThe Traumatic Brain Injury-Quality Of Life Fatigue (TBI-QOL) measures form part of the Promis Neuro-QOL initiative and include well-validated self-report measures that assess the health-related QOL of individuals with neurological disorders. All TBI-QOL scores have been transformed to a T metric,from 0-100, with a mean of 50 (SD = 10), with a higher score indicating more fatigue.
Actiwatch Spectrum - Mesor4 weeks post treatmentPhilips Actiwatch Spectrum to measure circadian rhythms; it is the size and shape of a digital wristwatch and weighs about one ounce. It is worn on an ordinary watchband and is waterproof. Data can be downloaded and analyzed using Actiware software. The Actiwatch Spectrum logs all physical movement using a piezoelectric accelerometer and detects the presence of ambient light (400-700nm), making it a useful measure of circadian cycles because it allows for accurate quantitative assessment of periods of activity, rest and sleep. Mesor is an adjusted proportion of the difference between the minimum and half the peak, so range is 0-1. Higher means a more rhythmic pattern.
Actiwatch Spectrum - F Statistic4 weeks post treatmentPhilips Actiwatch Spectrum to measure circadian rhythms; it is the size and shape of a digital wristwatch and weighs about one ounce. It is worn on an ordinary watchband and is waterproof. Data can be downloaded and analyzed using Actiware software. The Actiwatch Spectrum logs all physical movement using a piezoelectric accelerometer and detects the presence of ambient light (400-700nm), making it a useful measure of circadian cycles because it allows for accurate quantitative assessment of periods of activity, rest and sleep. F statistic is an F value, so the range is 0 - infinity. It compares two different models of calculating the curve. Higher means a more rhythmic pattern.
Satisfaction With Life Scalebaseline, 4 weeks, 8 weeksSatisfaction with Life Scale, a 5-item measure of global satisfaction with life, on likert scale from 1 strongly disagree to 7 strongly agree. Total scale from 5 to 35, with higher scores indicating more satisfaction with life, and 20 representing a neutral point on the scale.
Treatment Satisfaction Questionnaire for Medicationat 4 weeks (end-of-treatment)An adapted version of the Treatment Satisfaction Questionnaire for Medication (TSQM). This is a validated, psychometrically sound measure of general treatment satisfaction. The TSQM scores range from 0 to 100 with higher scores representing higher satisfaction.
Credibility/Expectancy Questionnaireat 4 weeks (end-of-treatment)Assess treatment credibility (BWL vs. DRL) with the Credibility/Expectancy Questionnaire (CEQ), used in clinical outcome studies. The CEQ utilizes two scales during the administration (1-9, and 0-100%), and so a composite z score was derived for each factor (expectancy and credibility) by first standardizing the individual items and then summing those items for each factor. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean. A higher score indicates more belief or feeling of reduction in anxiety.
Actiwatch Spectrum - Acrophase4 weeks post treatmentPhilips Actiwatch Spectrum to measure circadian rhythms; it is the size and shape of a digital wristwatch and weighs about one ounce. It is worn on an ordinary watchband and is waterproof. Data can be downloaded and analyzed using Actiware software. The Actiwatch Spectrum logs all physical movement using a piezoelectric accelerometer and detects the presence of ambient light (400-700nm), making it a useful measure of circadian cycles because it allows for accurate quantitative assessment of periods of activity, rest and sleep. Acrophase is time of the peak activity, so it is expressed in hours. The higher the number, the later in the day the peak activity occurs.

Countries

United States

Participant flow

Recruitment details

From October 2015-January 2017, recruitment materials were sent to previous research and support group participants, and other local TBI centers. Information was also posted online and at consumer conferences. External sites included Centre for Neuro Skills facilities and post-acute rehab centers in Bakersfield and Los Angeles, CA, and Dallas, TX.

Participants by arm

ArmCount
Bright White Light (BWL)
Participants will self-administer bright white light daily using a Litebook® (The Litebook Company Ltd.). The Litebook is a small (6 x 5 x 1) and lightweight (8 oz.) box.
44
Dim Red Light (DRL)
Participants will self-administer dim red light daily using a device that appears identical to Bright White Light (BWL) Litebook but that uses red LEDs emitting DRL.
44
Total88

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event10
Overall StudyLost to Follow-up11
Overall StudyWithdrawal by Subject09

Baseline characteristics

CharacteristicBright White Light (BWL)Dim Red Light (DRL)Total
Age, Continuous48.045 years
STANDARD_DEVIATION 16.335
45.182 years
STANDARD_DEVIATION 13.138
46.614 years
STANDARD_DEVIATION 14.808
Race/Ethnicity, Customized
Asian/Pacific Islander
2 Participants5 Participants7 Participants
Race/Ethnicity, Customized
Black or African American
6 Participants5 Participants11 Participants
Race/Ethnicity, Customized
Hispanic/Latino
5 Participants8 Participants13 Participants
Race/Ethnicity, Customized
More than one race/Other
4 Participants3 Participants7 Participants
Race/Ethnicity, Customized
White
27 Participants23 Participants50 Participants
Sex: Female, Male
Female
20 Participants24 Participants44 Participants
Sex: Female, Male
Male
24 Participants20 Participants44 Participants
Years of education completed15.841 years
STANDARD_DEVIATION 2.533
15.651 years
STANDARD_DEVIATION 2.654
15.747 years
STANDARD_DEVIATION 2.58

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 440 / 44
other
Total, other adverse events
1 / 440 / 44
serious
Total, serious adverse events
0 / 440 / 44

Outcome results

Primary

Multidimensional Assessment of Fatigue (MAF)

Multidimensional Assessment of Fatigue (MAF) yields a Global Fatigue Index (GFI), assessing 5 dimensions of fatigue: distress, degree, severity, impact on ADLs and frequency of fatigue in the past week, and it yields a composite score. GFI full score from 0-50, with a higher score indicating more severe fatigue, fatigue distress, or impact on activities of daily living.

Time frame: baseline, 4 weeks, 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Bright White Light (BWL)Multidimensional Assessment of Fatigue (MAF)Baseline33.332 score on a scaleStandard Deviation 9.043
Bright White Light (BWL)Multidimensional Assessment of Fatigue (MAF)4 weeks (end of treatment)27.993 score on a scaleStandard Deviation 9.993
Bright White Light (BWL)Multidimensional Assessment of Fatigue (MAF)8 weeks (one month post treatment)28.658 score on a scaleStandard Deviation 12.213
Dim Red Light (DRL)Multidimensional Assessment of Fatigue (MAF)Baseline30.531 score on a scaleStandard Deviation 10.633
Dim Red Light (DRL)Multidimensional Assessment of Fatigue (MAF)4 weeks (end of treatment)24.937 score on a scaleStandard Deviation 10.558
Dim Red Light (DRL)Multidimensional Assessment of Fatigue (MAF)8 weeks (one month post treatment)25.350 score on a scaleStandard Deviation 10.895
Secondary

Actiwatch Spectrum - Acrophase

Philips Actiwatch Spectrum to measure circadian rhythms; it is the size and shape of a digital wristwatch and weighs about one ounce. It is worn on an ordinary watchband and is waterproof. Data can be downloaded and analyzed using Actiware software. The Actiwatch Spectrum logs all physical movement using a piezoelectric accelerometer and detects the presence of ambient light (400-700nm), making it a useful measure of circadian cycles because it allows for accurate quantitative assessment of periods of activity, rest and sleep. Acrophase is time of the peak activity, so it is expressed in hours. The higher the number, the later in the day the peak activity occurs.

Time frame: 4 weeks post treatment

Population: After the Actigraph data were cleaned and analyzed, there was clean, usable data for 30 in the white arm and 23 in the red arm.

ArmMeasureValue (MEAN)Dispersion
Bright White Light (BWL)Actiwatch Spectrum - Acrophase15.68 hoursStandard Deviation 2.29
Dim Red Light (DRL)Actiwatch Spectrum - Acrophase15.98 hoursStandard Deviation 1.09
Secondary

Actiwatch Spectrum - F Statistic

Philips Actiwatch Spectrum to measure circadian rhythms; it is the size and shape of a digital wristwatch and weighs about one ounce. It is worn on an ordinary watchband and is waterproof. Data can be downloaded and analyzed using Actiware software. The Actiwatch Spectrum logs all physical movement using a piezoelectric accelerometer and detects the presence of ambient light (400-700nm), making it a useful measure of circadian cycles because it allows for accurate quantitative assessment of periods of activity, rest and sleep. F statistic is an F value, so the range is 0 - infinity. It compares two different models of calculating the curve. Higher means a more rhythmic pattern.

Time frame: 4 weeks post treatment

Population: After the Actigraph data were cleaned and analyzed, there was clean, usable data for 30 in the white arm and in the 23 red arm.

ArmMeasureValue (MEAN)Dispersion
Bright White Light (BWL)Actiwatch Spectrum - F Statistic1765.36 score on a scaleStandard Deviation 1120.32
Dim Red Light (DRL)Actiwatch Spectrum - F Statistic2307.38 score on a scaleStandard Deviation 1574.54
Secondary

Actiwatch Spectrum - Mesor

Philips Actiwatch Spectrum to measure circadian rhythms; it is the size and shape of a digital wristwatch and weighs about one ounce. It is worn on an ordinary watchband and is waterproof. Data can be downloaded and analyzed using Actiware software. The Actiwatch Spectrum logs all physical movement using a piezoelectric accelerometer and detects the presence of ambient light (400-700nm), making it a useful measure of circadian cycles because it allows for accurate quantitative assessment of periods of activity, rest and sleep. Mesor is an adjusted proportion of the difference between the minimum and half the peak, so range is 0-1. Higher means a more rhythmic pattern.

Time frame: 4 weeks post treatment

Population: After the Actigraph data were cleaned and analyzed, there was clean, usable data for 30 in the white arm and 23 in the red arm.

ArmMeasureValue (MEAN)Dispersion
Bright White Light (BWL)Actiwatch Spectrum - Mesor0.72 score on a scaleStandard Deviation 0.21
Dim Red Light (DRL)Actiwatch Spectrum - Mesor0.83 score on a scaleStandard Deviation 0.25
Secondary

CNS Vital Signs TBI Rehab Toolbox

The Centre for Neuro Skills Vital Signs TBI Rehab Toolbox is a brief, 25-minute computerized cognition battery; it emphasizes those cognitive functions that are the most likely to respond to alerting effects of light (vigilance, attention, speed) and has multiple forms for serial assessment. The scores are reported as Standard Scores, with mean = 100 and standard deviation = 15. Higher scores are correlated with better outcomes.

Time frame: baseline, 4 weeks, 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Bright White Light (BWL)CNS Vital Signs TBI Rehab Toolboxbaseline79.59 score on a scaleStandard Deviation 26.26
Bright White Light (BWL)CNS Vital Signs TBI Rehab Toolbox4 weeks (end of treatment)83.19 score on a scaleStandard Deviation 27.489
Bright White Light (BWL)CNS Vital Signs TBI Rehab Toolbox8 weeks (one month post treatment)86.17 score on a scaleStandard Deviation 28.051
Dim Red Light (DRL)CNS Vital Signs TBI Rehab Toolboxbaseline82.83 score on a scaleStandard Deviation 21.805
Dim Red Light (DRL)CNS Vital Signs TBI Rehab Toolbox4 weeks (end of treatment)77.64 score on a scaleStandard Deviation 37.658
Dim Red Light (DRL)CNS Vital Signs TBI Rehab Toolbox8 weeks (one month post treatment)79.10 score on a scaleStandard Deviation 35.443
Secondary

Cognitive Failures Questionnaire

The Cognitive Failures Questionnaire (CFQ)100 is a 25-item self-report inventory, with items measuring difficulties in several cognitive domains (e.g., memory, perception), each item scored from 0 (never) to 4 (very often), with total scale from 0 - 100, with higher score indicating worse outcome.

Time frame: baseline, 4 weeks, 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Bright White Light (BWL)Cognitive Failures Questionnairebaseline47.823 score on a scaleStandard Deviation 16.872
Bright White Light (BWL)Cognitive Failures Questionnaire4 weeks (end of treatment)45.261 score on a scaleStandard Deviation 17.59
Bright White Light (BWL)Cognitive Failures Questionnaire8 weeks (one month post treatment)47.503 score on a scaleStandard Deviation 18.204
Dim Red Light (DRL)Cognitive Failures Questionnairebaseline42.806 score on a scaleStandard Deviation 15.175
Dim Red Light (DRL)Cognitive Failures Questionnaire4 weeks (end of treatment)46.564 score on a scaleStandard Deviation 16.646
Dim Red Light (DRL)Cognitive Failures Questionnaire8 weeks (one month post treatment)45.352 score on a scaleStandard Deviation 18.31
Secondary

Credibility/Expectancy Questionnaire

Assess treatment credibility (BWL vs. DRL) with the Credibility/Expectancy Questionnaire (CEQ), used in clinical outcome studies. The CEQ utilizes two scales during the administration (1-9, and 0-100%), and so a composite z score was derived for each factor (expectancy and credibility) by first standardizing the individual items and then summing those items for each factor. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean. A higher score indicates more belief or feeling of reduction in anxiety.

Time frame: at 4 weeks (end-of-treatment)

Population: Compared to other outcome measures, fewer CEQ records were analyzed due to participant non-compliance.

ArmMeasureValue (MEAN)Dispersion
Bright White Light (BWL)Credibility/Expectancy Questionnaire-.5539 score on a scaleStandard Deviation 2.577
Dim Red Light (DRL)Credibility/Expectancy Questionnaire.4489 score on a scaleStandard Deviation 2.74
Secondary

Epworth Sleepiness Scale (ESS)

The Epworth Sleepiness Scale (ESS) will also be used, to assess daytime sleepiness; it is an 8-item measure that asks about the probability of dozing or sleeping during typical daytime activities and has been widely used in TBI research. Scores correlate well with objective measures of speed of daytime sleep onset. The test is a list of eight situations in which the participate rates tendency to become sleepy on a scale of 0, no chance of dozing, to 3, high chance of dozing for each item. Total scale from 0 to 24, with higher score indicating severe excessive daytime sleepiness.

Time frame: baseline, 4 weeks, 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Bright White Light (BWL)Epworth Sleepiness Scale (ESS)baseline9.695 score on a scaleStandard Deviation 4.869
Bright White Light (BWL)Epworth Sleepiness Scale (ESS)4 weeks (end of treatment)8.162 score on a scaleStandard Deviation 3.927
Bright White Light (BWL)Epworth Sleepiness Scale (ESS)8 weeks (one month post treatment)8.169 score on a scaleStandard Deviation 4.041
Dim Red Light (DRL)Epworth Sleepiness Scale (ESS)baseline6.970 score on a scaleStandard Deviation 4.323
Dim Red Light (DRL)Epworth Sleepiness Scale (ESS)4 weeks (end of treatment)8.312 score on a scaleStandard Deviation 3.182
Dim Red Light (DRL)Epworth Sleepiness Scale (ESS)8 weeks (one month post treatment)8.133 score on a scaleStandard Deviation 3.899
Secondary

Neuro-QOL Anxiety

The Neuro-QOL Anxiety measure. Raw scores were converted to T-Scores; from 0-100, with a T = 50 indicating average function compared to the reference population and a standard deviation of 10, with a higher score indicating worse anxiety.

Time frame: baseline, 4 weeks, 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Bright White Light (BWL)Neuro-QOL Anxietybaseline55.725 T scoreStandard Deviation 8.137
Bright White Light (BWL)Neuro-QOL Anxiety4 weeks (end of treatment)55.250 T scoreStandard Deviation 8.929
Bright White Light (BWL)Neuro-QOL Anxiety8 weeks (one month post treatment)57.441 T scoreStandard Deviation 8.073
Dim Red Light (DRL)Neuro-QOL Anxietybaseline56.253 T scoreStandard Deviation 7.581
Dim Red Light (DRL)Neuro-QOL Anxiety4 weeks (end of treatment)56.661 T scoreStandard Deviation 7.766
Dim Red Light (DRL)Neuro-QOL Anxiety8 weeks (one month post treatment)55.226 T scoreStandard Deviation 8.828
Secondary

Neuro-QOL Depression and Sleep

The Neuro-QOL Depression and Sleep measures the physical, mental, and social effects experienced by adults and children living with neurological conditions. Raw scores were converted to T-Scores; from 0-100, with a T = 50 indicating average function compared to the reference population and a standard deviation of 10, with a higher score indicating worse function.

Time frame: baseline, 4 weeks, 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Bright White Light (BWL)Neuro-QOL Depression and SleepBaseline52.893 T-scoreStandard Deviation 8.033
Bright White Light (BWL)Neuro-QOL Depression and Sleep4 weeks (end of treatment)53.337 T-scoreStandard Deviation 8.19
Bright White Light (BWL)Neuro-QOL Depression and Sleep8 weeks (one month post treatment)55.162 T-scoreStandard Deviation 8.193
Dim Red Light (DRL)Neuro-QOL Depression and SleepBaseline82.942 T-scoreStandard Deviation 7.57
Dim Red Light (DRL)Neuro-QOL Depression and Sleep4 weeks (end of treatment)52.864 T-scoreStandard Deviation 7.896
Dim Red Light (DRL)Neuro-QOL Depression and Sleep8 weeks (one month post treatment)52.290 T-scoreStandard Deviation 9.698
Secondary

Satisfaction With Life Scale

Satisfaction with Life Scale, a 5-item measure of global satisfaction with life, on likert scale from 1 strongly disagree to 7 strongly agree. Total scale from 5 to 35, with higher scores indicating more satisfaction with life, and 20 representing a neutral point on the scale.

Time frame: baseline, 4 weeks, 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Bright White Light (BWL)Satisfaction With Life Scalebaseline17.409 score on a scaleStandard Deviation 6.956
Bright White Light (BWL)Satisfaction With Life Scale4 weeks (end of treatment)17.622 score on a scaleStandard Deviation 7.154
Bright White Light (BWL)Satisfaction With Life Scale8 weeks (one month post treatment)17.441 score on a scaleStandard Deviation 6.219
Dim Red Light (DRL)Satisfaction With Life Scalebaseline18.698 score on a scaleStandard Deviation 7.386
Dim Red Light (DRL)Satisfaction With Life Scale4 weeks (end of treatment)18.394 score on a scaleStandard Deviation 7.925
Dim Red Light (DRL)Satisfaction With Life Scale8 weeks (one month post treatment)19.900 score on a scaleStandard Deviation 6.707
Secondary

TBI-QOL Fatigue

The Traumatic Brain Injury-Quality Of Life Fatigue (TBI-QOL) measures form part of the Promis Neuro-QOL initiative and include well-validated self-report measures that assess the health-related QOL of individuals with neurological disorders. All TBI-QOL scores have been transformed to a T metric,from 0-100, with a mean of 50 (SD = 10), with a higher score indicating more fatigue.

Time frame: baseline, 4 weeks, 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Bright White Light (BWL)TBI-QOL FatigueBaseline61.819 T scoreStandard Deviation 6.255
Bright White Light (BWL)TBI-QOL Fatigue4 weeks (end of treatment)58.071 T scoreStandard Deviation 7.384
Bright White Light (BWL)TBI-QOL Fatigue8 weeks (one month post treatment)58.226 T scoreStandard Deviation 8.481
Dim Red Light (DRL)TBI-QOL FatigueBaseline58.821 T scoreStandard Deviation 7.533
Dim Red Light (DRL)TBI-QOL Fatigue4 weeks (end of treatment)55.724 T scoreStandard Deviation 8.305
Dim Red Light (DRL)TBI-QOL Fatigue8 weeks (one month post treatment)57.252 T scoreStandard Deviation 9.033
Secondary

Treatment Satisfaction Questionnaire for Medication

An adapted version of the Treatment Satisfaction Questionnaire for Medication (TSQM). This is a validated, psychometrically sound measure of general treatment satisfaction. The TSQM scores range from 0 to 100 with higher scores representing higher satisfaction.

Time frame: at 4 weeks (end-of-treatment)

ArmMeasureValue (MEDIAN)Dispersion
Bright White Light (BWL)Treatment Satisfaction Questionnaire for Medication42.455 score on a scaleStandard Deviation 29.827
Dim Red Light (DRL)Treatment Satisfaction Questionnaire for Medication47.546 score on a scaleStandard Deviation 33.112

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026